chr15-48456688-A-G
Variant summary
Our verdict is Pathogenic. Variant got 19 ACMG points: 19P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_000138.5(FBN1):c.5371T>C(p.Cys1791Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 11/18 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. C1791Y) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000138.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 19 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FBN1 | NM_000138.5 | c.5371T>C | p.Cys1791Arg | missense_variant | 44/66 | ENST00000316623.10 | NP_000129.3 | |
FBN1 | NM_001406716.1 | c.5371T>C | p.Cys1791Arg | missense_variant | 43/65 | NP_001393645.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FBN1 | ENST00000316623.10 | c.5371T>C | p.Cys1791Arg | missense_variant | 44/66 | 1 | NM_000138.5 | ENSP00000325527.5 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Marfan syndrome Pathogenic:2
Pathogenic, no assertion criteria provided | clinical testing | Center for Medical Genetics Ghent, University of Ghent | Nov 07, 2017 | - - |
Pathogenic, criteria provided, single submitter | research | Centre of Medical Genetics, University of Antwerp | Mar 01, 2021 | PM2, PVS2, PP4 - |
Familial thoracic aortic aneurysm and aortic dissection Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Sep 09, 2022 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 24, 2018 | The p.C1791R variant (also known as c.5371T>C), located in coding exon 43 of the FBN1 gene, results from a T to C substitution at nucleotide position 5371. The cysteine at codon 1791 is replaced by arginine, an amino acid with highly dissimilar properties, and is located in the cbEGF-like #25 domain. This alterations has been detected in individuals reported to have Marfan syndrome or related features (Rommel K et al. Hum Mutat. 2005;26:529-39; Ogawa N et al. Am J Cardiol. 2011;108:1801-7). Other alterations affecting this amino acid, p.C1791Y and p.C1791F, have also been reported in association with Marfan syndrome (Loeys B et al. Arch Intern Med. 2001;161:2447-54; Howarth R et al. Genet Test. 2007;11:146-52). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on internal structural assessment, this alteration eliminates a structurally critical disulfide in the structurally sensitive cbEGF-like domain #25. Furthermore, the majority of FBN1 mutations identified to date have involved the substitution or generation of cysteine residues within cbEGF domains (Vollbrandt T et al. J Biol Chem. 2004;279(31):32924-32931). Based on the majority of available evidence to date, this alteration is likely to be pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Aug 27, 2018 | The C1791R pathogenic variant in the FBN1 gene has been previously reported in association with Marfan syndrome (Rommel et al., 2005; Ogawa et al., 2011). Rommel et al. (2005) identified this variant in two sisters diagnosed with classic Marfan syndrome per Ghent diagnostic criteria. Subsequently, C1791R was reported in one individual from a cohort of 53 Japanese individuals suspected of having Marfan syndrome, although further clinical details as to whether this individual fulfilled Ghent diagnostic criteria were not available (Ogawa et al., 2011). This variant is also not observed in large population cohorts (Lek et al., 2016). The C1791R variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. Additionally, this substitution occurs at a position that is conserved across species and in silico analysis predicts this variant is probably damaging to the protein structure/function. Furthermore, C1791R affects a Cysteine residue within a calcium-binding EGF-like domain of the FBN1 gene, which may affect disulfide bonding and is predicted to alter the structure and function of the protein. Cysteine substitutions in the calcium-binding EGF-like domains represent the majority of pathogenic missense changes associated with FBN1-related disorders (Collod-Beroud et al., 2003). Finally, other pathogenic/likely pathogenic variants at the same residue (C1791Y, C1791F) have also been reported in association with FBN1-related disorders (Loeys et al., 2001; Howarth et al., 2007), supporting the functional importance of this residue. - |
Marfan syndrome;C4707243:Familial thoracic aortic aneurysm and aortic dissection Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 15, 2023 | This sequence change replaces cysteine, which is neutral and slightly polar, with arginine, which is basic and polar, at codon 1791 of the FBN1 protein (p.Cys1791Arg). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with Marfan syndrome (PMID: 16220557; Invitae). ClinVar contains an entry for this variant (Variation ID: 449439). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt FBN1 protein function with a positive predictive value of 95%. This variant affects a cysteine residue in the EGF-like, TGFBP or hybrid motif domains of FBN1. Cysteine residues are believed to be involved in intramolecular disulfide bridges and have been shown to be important for FBN1 protein structure (PMID: 16905551, 19349279). In addition, missense substitutions affecting cysteine residues within these domains are significantly overrepresented among patients with Marfan syndrome (PMID: 16571647, 17701892). For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at